We’re thrilled to share that our "Do You See It?" campaign with Agios Pharmaceuticals has been named MM+M's Campaign of the Week! Discover the hidden dangers of #thalassemia and the innovative approach we took to raise awareness here: https://ow.ly/fklw50SyKGg
EVERSANA INTOUCH’s Post
More Relevant Posts
-
Nipocalimab's potential to redefine treatment paradigms for generalized myasthenia gravis is a noteworthy development in the healthcare landscape. With promising Phase 3 results and ambitions for broader applications, J&J positions itself in a competitive arena of FcRn blockers. This evolution emphasizes the importance of creativity and strategy in pharmaceutical marketing. As we navigate these changes, let’s explore innovative ways to convey patient benefits and drive engagement.
J&J submits touted autoimmune disease drug for FDA approval
biopharmadive.com
To view or add a comment, sign in
-
Thoughts on this? >> Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #biotech #healthcare
Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up
fiercebiotech.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharmaceutical #pharma
Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up
fiercebiotech.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #competitivemarketing
Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years
fiercebiotech.com
To view or add a comment, sign in
-
Takeda’s resurrection of the once-rejected #Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s big blockbuster drug. The FDA rejected Eohilia, also called TAK-721 , in the chronic inflammatory disease eosinophilic esophagitis in 2021. Spherix Global Insights surveyed 75 U.S. physicians who treat #eosinophilic #esophagitis was found trial rates to be comparable to DUPIXENT® (dupilumab) HCP, which won FDA approval in the setting in 2022, at a similar point in its launch. More than half of the physicians had prescribed Eohilia and “the breadth of patient initiations” for Takeda’s drug surpassed that of #Dupixent, Spherix said. Projecting out to six months after launch suggests a user base comparable to that of Dupixent. Spherix expects Takeda’s market share to increase by fourfold. The forecasts reflect the potential for Eohilia to fill a gap in the toolkit for treating eosinophilic esophagitis
Docs embrace Takeda's Eohilia, creating competition for Sanofi, Regeneron's blockbuster Dupixent
fiercepharma.com
To view or add a comment, sign in
-
Thoughts on this? >> Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #pharmaceutical #healthcare #biotech
Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years
fiercebiotech.com
To view or add a comment, sign in
-
Now that the #IgAN arsenal of effective drugs has come to fruition, it's an opportune time to measure long-term outcomes and #HCRU in current SoC. This would facilitate the next stage of gaining reimbursement, armed with quality benchmark estimates to model cost-effectiveness and #ICERs. #healthcare #pharmaceuticals
Travere Wins Full FDA Approval for IgAN Treatment Filspari
biospace.com
To view or add a comment, sign in
-
Biogen needs Leqembi to be successful following discontinuation of Aduhelm, says GlobalData "Biogen focuses on the success of Leqembi after discontinuing Aduhelm. The firm's strategic shift is noteworthy in the healthcare field. Reinforcing its position in the market, it's a pivotal moment for Biogen." #Biogen #Leqembi #HealthcareIndustry #Pharmaceuticals #MarketStrategy #ProductDevelopment #pharma #biotech #pharmiwebcom
Biogen needs Leqembi to be successful following discontinuation of Aduhelm, says GlobalData
pharmiweb.com
To view or add a comment, sign in
-
Global Marketing Lead at Bayer AG, “Working with cross functional/multi-cultural teams is my bread & butter, the heterogeneity of the discussions + managing the multitude of resulting options to act is the caviar on top”
Patient Engagement in the Pharmaceutical Industry is already an important standard in today. An interesting overview of the positions of several companies can be found here: https://lnkd.in/diJiWZhU Enjoy reading.
PATIENTVIEW_WHAT_COMPANIES_SAY_FINAL.pdf
patient-view.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> 'Clinical intuition' led FDA advisors to back Zevra's rare disease med >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #competitivemarketing #biotech
'Clinical intuition' led FDA advisors to back Zevra's rare disease med
fiercebiotech.com
To view or add a comment, sign in
31,152 followers